OOIR: Observatory of International Research

Papers

(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy	110
Imaging of brain metastases treated with immune checkpoint inhibitors	38
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study	29
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma	28
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	23
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	22
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	22
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	22
Postvaccination immune-mediated hepatitis: what do we really know?	21
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	20
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	20
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	19
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis	19
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives	18
Nivolumab induced discolouration of the tongue: a case report	18
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?	18
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers	18
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-27	17
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report	16
Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report	16
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	15
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?	15
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors	15
Cancer Immunotherapy Via Stem Cell-Derived NK Cells	15
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results	14

Adherence, persistence and treatment switching in psoriasis	14
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis	14
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors	14
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer	14
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins	13
Current Immunosuppression Strategies in Pediatric Heart Transplant	13
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	13
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma	13
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review	13
Immune Checkpoint Inhibitors in Cholangiocarcinoma	12
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report	12
Germinal center immune dynamics: challenges for effective vaccination in the elderly	12
Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study	11
Deucravacitinib in Moderate-To-Severe Psoriasis	11
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	11
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report	10
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management	10
Clinical optimization of bexmarilimab as a myeloid checkpoint therapy	10
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	10
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice	10
Liquid biopsy for guiding breast cancer immunotherapy	10
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma	10
Immune-Related Gigantomastia: A Case Study	10
Effectiveness of COVID-19 Vaccines Against Omicron Variant	10
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges	10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations	10
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary	10
Integrase inhibitors: current protagonists in antiretroviral therapy	10
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far	9
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens	9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	9
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	9
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies	9
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs	9
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab	9
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	9
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib	9
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis	9
Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis	9
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	9
Abrocitinib for the Treatment of Atopic Dermatitis	8
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients	8
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	8
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis	8
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis	8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma	8
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	8
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	8
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma	8
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report	8

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	8
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	7
Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival	7
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	7
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy	7
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	7
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	7
Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours	7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	7
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	7
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study	7
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	7
Immunotherapies for prevention and treatment of type 1 diabetes	7
Pembrolizumab in an HIV-infected patient with glioblastoma	7
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	7
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases	6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy	6
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature	6
Could senescent cells be the prescription for therapeutic cancer vaccines?	6
Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions	6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	6
Sublingual immunotherapy suppresses Th2-type immune response in the allergic rhinitis mouse model by inhibiting the activation of the NFκB pathway	6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary	6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy	6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	6
Allogeneic CAR-T cells for cancer immunotherapy	6
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease	6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?	6
Oncolytic Viruses in Lung Cancer Treatment: A Review Article	6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates	6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis	6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	6
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	6
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery	5
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease	5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults	5
Drug evaluation: mepolizumab in chronic obstructive pulmonary disease	5
The potential of CAR T cells in autoimmune diseases	5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment	5
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?	5
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy	5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy	5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents	5
Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis	5
Tsunami of Immunotherapies in the Management of Esophageal Cancer	5
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations	5
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review	5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature	5
Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy	5
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report	5
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study	5
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma	5
Immunotherapy of endometrial cancer: a review of recent advances	5
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression	5
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy	5
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial	5
The potential of phytomedicines to optimize CAR-T cell therapy in cancer	5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management	5
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer	5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	5
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors	5
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event	5
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis	5
Cost-utility analysis of blinatumomab in pediatric patients with acute lymphoblastic leukemia in Iran	5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	5
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer	5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study	5
Bimekizumab for The Treatment of Psoriasis	5
Plain language summary of disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT	5
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives	5
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review	5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review	5
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis	5